World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4174)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

161

WORD

HTML

2449

Figures (1-3)

347

Tables (1-4)

335

Sum=3301

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

173

Download

524

Sum=697

Feb 28, 2024 (publication date) through May 20, 2025

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Wu HX, Ding XY, Xu YW, Yu MH, Li XM, Deng N, Chen JL. Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol 2024; 30(8): 843-854 [PMID: 38516240 DOI: 10.3748/wjg.v30.i8.843]
URL:	https://www.wjgnet.com/1007-9327/full/v30/i8/843.htm

Number	Citing Articles
1	Daniele Ferraro, Federica Falaschi, Luca Nazzaro, Giovanni Vennarecci. Impact of neoadjuvant multimodal therapy in the setting of locally advanced hepatocellular carcinoma. World Journal of Gastroenterology 2024; 30(28): 3452-3455 doi: 10.3748/wjg.v30.i28.3452 Abstract(410) \| Core Tip(435) \| Full Article(HTML)(1199) \| Full Article with Cover (PDF)-691K(64) \| Audio-512K(3) \| Peer-Review Report-310K(51) \| Answering Reviewers-64K(51) \| Full Article (PDF)-346K(104) \| Full Article (XML)-48K(51) \| Times Cited (1) \| Total Visits (2874) \| Open
2	Yuhang Chen, Suoyi Dai, Chien-shan Cheng, Lianyu Chen. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. Journal of Hematology & Oncology 2024; 17(1) doi: 10.1186/s13045-024-01647-1
3	Changjie Du, Hongyu Wu, Tao Zhong, Qilong Zhai, Jiajun Yuan, Jialun Peng, Rong Ma, Jinzheng Li. Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. Discover Oncology 2024; 15(1) doi: 10.1007/s12672-024-01026-9
4	Yue Chen, Luyao Jia, Yu Li, Wenhao Cui, Jukun Wang, Chao Zhang, Chunjing Bian, Tao Luo. Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1466113
5	Deyu Lu, Lingling Zhou, Ziyi Zuo, Zhao Zhang, Xiangwu Zheng, Jialu Weng, Zhijie Yu, Jiansong Ji, Jinglin Xia. MRI Radiomics to Predict Early Treatment Response to TACE Combined with Lenvatinib Plus a PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Journal of Hepatocellular Carcinoma 2025; : 985 doi: 10.2147/JHC.S513696